SCHEMBL6551670

SCHEMBL6551670

O=CNc1nc(Cl)c2nc[nH]c2n1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL7594621 0.91
SCHEMBL8369704 0.80 MEN1 (0.32)
SCHEMBL14110227 0.77 XDH (0.38)
SCHEMBL14260670 0.77 CSNK2A1 (0.32) DPP4
SCHEMBL6551675 0.75 DPP4 (0.56) DPP4
SCHEMBL15064128 0.75 EGLN1 (0.32) DPP4
SCHEMBL5197095 0.74 CYP1A2 (0.39)
SCHEMBL15747660 0.73
SCHEMBL9412739 0.73 MAPT (0.35)
SCHEMBL8588214 0.73 KMT2A (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452004-B1 USEFUL AS AN INTERMEDIATE OF A CARBOCYCLIC NUCLEOSIDE USEFULLY USED AS AN ANTI-VIRAL AGENT KURARAY CO., LTD. (JP) 2002-09-17 US claimed
EP-0773220-B1 2-Amino-6-chloropurine and method for preparing the same SUMIKA FINE CHEMICALS CO LTD (JP) 2002-02-13 EP claimed
EP-0861841-B1 PROCESS FOR PRODUCING 2-AMINO-6-IODOPURINE SUMIKA FINE CHEMICALS COMPANY (JP) 2001-04-04 EP claimed
US-6127539-A Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein KURARAY CO., LTD. (JP) 2000-10-03 US claimed
US-5994541-A Process for producing 2-amino-6-iodopurine SUMIKA FINE CHEMICALS CO., LTD. (JP) 1999-11-30 US claimed
US-5817812-A Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein KURARAY CO., LTD. (JP) 1998-10-06 US claimed
EP-0861841-A1 PROCESS FOR PRODUCING 2-AMINO-6-IODOPURINE SUMIKA FINE CHEMICALS Company, Limited (JP) 1998-09-02 EP claimed
US-5789590-A Double cone-like crystal form of 2-amino-6-chloropurine and preparation SUMIKA FINE CHEMICALS CO., LTD. (JP) 1998-08-04 US claimed
EP-0773220-A1 2-Amino-6-chloropurine and method for preparing the same SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1997-05-14 EP claimed
JP-10077284-A None JP disclosed
JP-9188681-A None JP disclosed
US-20100204463-A1 Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation EMORY UNIVERSITY 2010-08-12 US disclosed
US-20100204463-A1 Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation EMORY UNIVERSITY 2010-08-12 US disclosed
EP-1394163-A1 Bicycloamide derivatives Kuraray Co., Ltd. (JP) 2004-03-03 EP disclosed
EP-0775705-A2 Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein KURARAY CO., LTD. (JP) 1997-05-28 EP disclosed
EP-0773220-A1 2-Amino-6-chloropurine and method for preparing the same SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1997-05-14 EP disclosed
US-5440037-A Method for production of 2-amino-6-halogenopurine derivatives SUMIKA FINE CHEMICALS CO., LTD. (JP) 1995-08-08 US disclosed
US-5391733-A Synthesis intermediates for 2-amino-6-halogenopurines SUMIKA FINE CHEMICALS CO., LTD. (JP) 1995-02-21 US disclosed
US-5389637-A 2-formylamino-6-halogenopurine SUMIKA FINE CHEMICALS CO., LTD. (JP) 1995-02-14 US disclosed
EP-0543095-A2 Method for producing 2-amino-6-halogenopurine and synthesis intermediate therefor SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1993-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204463-A1 Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation PAICS, POLRMT, ZC3HAV1 DPP4 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.